<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04053803</url>
  </required_header>
  <id_info>
    <org_study_id>IMR-SCD-102-EXT</org_study_id>
    <secondary_id>2018-003805-25</secondary_id>
    <nct_id>NCT04053803</nct_id>
  </id_info>
  <brief_title>An Extension Study of IMR-687 in Adult Patients With Sickle Cell Anemia</brief_title>
  <official_title>An Open-label Extension Study of IMR-687 in Adult Patients With Sickle Cell Anemia (Homozygous HbSS or Sickle-β0 Thalassemia) Who Participated in Study IMR-SCD-102</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imara, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imara, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label extension study of IMR-687 in adult patients who completed Imara's&#xD;
      blinded Phase 2a study (IMR-SCD-102). The open-label extension study will evaluate long-term&#xD;
      safety and tolerability.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label extension study of IMR-687 in adult patients with SCA who were&#xD;
      previously participants in the Phase 2a study titled &quot;A Phase 2a, Randomised, Double-Blind,&#xD;
      Placebo-Controlled Study of IMR-687 in Adult Patients with Sickle Cell Anaemia (Homozygous&#xD;
      HbSS or Sickle-β0 Thalassemia).&quot;&#xD;
&#xD;
      This open-label extension study with IMR-687 will evaluate the long-term safety and&#xD;
      tolerability of IMR 687 in adult SCA patients. Exploratory long-term PD parameters will also&#xD;
      be examined.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">May 22, 2019</start_date>
  <completion_date type="Anticipated">March 2025</completion_date>
  <primary_completion_date type="Anticipated">March 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with adverse events and serious adverse events</measure>
    <time_frame>Baseline to Month 49</time_frame>
    <description>Incidence of Adverse Events&#xD;
Incidence of Serious Adverse Events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients with changes in safety cardiac parameters</measure>
    <time_frame>Baseline to Month 49</time_frame>
    <description>a. Changes in 12-lead ECG parameters that are clinically significant and measured in milliseconds (ms).&#xD;
The parameters are: PR interval, QRS duration, QT interval, ST segment duration and T wave duration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients with changes in clinical laboratory tests</measure>
    <time_frame>Baseline to Month 49</time_frame>
    <description>a. Clinically significant changes in clinical laboratory tests including serum chemistry, serum hematology and urinalysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients with clinically significant abnormal vital signs</measure>
    <time_frame>Baseline to Month 49</time_frame>
    <description>Blood pressure measured in mmHg&#xD;
Pulse measured in beats per minute&#xD;
Respiration rate measured in breaths per minutes&#xD;
Temperature as measured in degrees F0 or C0</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>Open Label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMR-687</intervention_name>
    <description>Oral administration of once daily IMR-687</description>
    <arm_group_label>Open Label</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Completed Study IMR-SCD-102.&#xD;
&#xD;
          2. Female subjects must not be pregnant, not be breast feeding, and be highly unlikely to&#xD;
             become pregnant. Male subjects must be unlikely to impregnate a partner.&#xD;
&#xD;
          3. Subjects must be capable of giving informed consent and reading and signing the&#xD;
             informed consent form after the nature of the study has been fully explained to them&#xD;
&#xD;
          4. Subjects must be willing and able to complete all study assessments and procedures and&#xD;
             to communicate effectively with the investigator and site staff.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with Hb &gt;12.5 g/dL or &lt;6 g/dL&#xD;
&#xD;
          2. Subjects with known active hepatitis B or hepatitis C, with active or acute event of&#xD;
             malaria or who are known to be positive for human immunodeficiency virus (HIV)&#xD;
&#xD;
          3. eGFR &lt;50 mL/min&#xD;
&#xD;
          4. AST/ALT &gt; 3x the upper limit of normal&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eleanor Lisbon, MD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Imara, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Connecticut Health Center</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foundation for Sickle Cell Disease Research</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Scott &amp; White Medical Center - Temple</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bristol Haematology and Oncology Centre</name>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College London Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>NW1 2PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guy's and St Thomas Hospital CRF</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal London Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>July 18, 2019</study_first_submitted>
  <study_first_submitted_qc>August 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2019</study_first_posted>
  <last_update_submitted>September 29, 2020</last_update_submitted>
  <last_update_submitted_qc>September 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

